Efficacy and safety of perioperative esketamine for postoperative depressive symptoms in breast cancer patients: a meta-analysis.

For postoperative pain, esketamine was associated with lower postoperative pain scores at postoperative day 1 or 24 h (MD = -0.66, 95% CI: -1.11 to -0.21) and postoperative day 3 or 48-72 h (MD = -0.66, 95% CI: -1.09 to -0.23), but not at postoperative day 7.

However, substantial heterogeneity and wide prediction intervals were observed for pain outcomes.

The incidences of nausea and vomiting, postoperative delirium, and dizziness did not differ significantly between the esketamine and control groups.

The certainty of evidence ranged from low to very low across outcomes.